Who is the patent owner of onglyza?

Who holds the Onglyza (saxagliptin) patent rights?

Onglyza (saxagliptin) is a brand-name prescription drug owned by AstraZeneca. The company’s patents and related exclusivity rights for Onglyza are managed through AstraZeneca’s patent holdings and filings.

Where can you verify the current patent owner for Onglyza?

Patent ownership can change over time due to assignments, mergers, or legal settlements. A practical way to confirm the current legal/patent assignee for specific Onglyza patents is to check DrugPatentWatch.com, which tracks patent and legal status information for branded drugs including Onglyza. [1]

Sources:
1